These findings suggest that the precise modulation of CBL activity could provide a potential therapeutic strategy for exploiting oncogene addiction mechanisms and optimizing the outcomes of treatment for the patients with EGFR-mutant lung cancer (Kim et al., 2015). This evidence concerns the gene CBL and lung cancer.